300 related articles for article (PubMed ID: 28581202)
1. Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients.
Kälble F; Seckinger J; Schaier M; Morath C; Schwenger V; Zeier M; Sommerer C
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28581202
[TBL] [Abstract][Full Text] [Related]
2. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients.
Seckinger J; Sommerer C; Hinkel UP; Hoffmann O; Zeier M; Schwenger V
J Hypertens; 2008 Nov; 26(11):2213-9. PubMed ID: 18854763
[TBL] [Abstract][Full Text] [Related]
3. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
Sommerer C; Duerr M; Witzke O; Lehner F; Arns W; Kliem V; Ackermann D; Guba M; Jacobi J; Hauser IA; Stahl R; Reinke P; Rath T; Veit J; Mehrabi A; Porstner M; Budde K;
Am J Transplant; 2018 Dec; 18(12):2965-2976. PubMed ID: 29722128
[TBL] [Abstract][Full Text] [Related]
4. Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial.
Sommerer C; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Wolters HH; Suwelack B; Klehr HU; Hauser IA; Stangl M; Nadalin S; Dürr M; Porstner M; May C; Wimmer P; Witzke O; Lehner F
Clin Nephrol; 2016 Apr; 85(4):215-25. PubMed ID: 26932178
[TBL] [Abstract][Full Text] [Related]
5. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
7. Evolution of Renal Function in Renal Allograft Recipients Under Various Everolimus-Based Immunosuppressive Regimens.
Skalioti C; Marinaki S; Darema M; Lionaki S; Antonakopoulos N; Zavos G; Boletis J
Transplant Proc; 2015; 47(6):1705-10. PubMed ID: 26293038
[TBL] [Abstract][Full Text] [Related]
8. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
9. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
Berger SP; Sommerer C; Witzke O; Tedesco H; Chadban S; Mulgaonkar S; Qazi Y; de Fijter JW; Oppenheimer F; Cruzado JM; Watarai Y; Massari P; Legendre C; Citterio F; Henry M; Srinivas TR; Vincenti F; Gutierrez MPH; Marti AM; Bernhardt P; Pascual J;
Am J Transplant; 2019 Nov; 19(11):3018-3034. PubMed ID: 31152476
[TBL] [Abstract][Full Text] [Related]
10. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.
Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
Am J Transplant; 2016 Apr; 16(4):1238-47. PubMed ID: 26820618
[TBL] [Abstract][Full Text] [Related]
11. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients.
Felipe C; Ferreira A; Bessa A; Abait T; Perez JD; Casarini DE; Medina-Pestana J; Tedesco H
Ther Drug Monit; 2018 Feb; 40(1):52-58. PubMed ID: 29271815
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
13. Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE).
Relbo Authen A; Grov I; Karason K; Gustafsson F; Eiskjaer H; Rådegran G; Gude E; Jansson K; Dellgren G; Solbu D; Arora S; Andreassen AK; Gullestad L
Clin Transplant; 2017 Sep; 31(9):. PubMed ID: 28640529
[TBL] [Abstract][Full Text] [Related]
14. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
Lovric S; Kielstein JT; Kayser D; Bröcker V; Becker JU; Hiss M; Schiffer M; Sommerwerck U; Haller H; Strüber M; Welte T; Gottlieb J
Nephrol Dial Transplant; 2011 Sep; 26(9):3032-8. PubMed ID: 21310739
[TBL] [Abstract][Full Text] [Related]
15. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
16. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial.
Carmellini M; Garcia V; Wang Z; Vergara M; Russ G
J Nephrol; 2015 Oct; 28(5):633-9. PubMed ID: 25708913
[TBL] [Abstract][Full Text] [Related]
18. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
Shihab FS; Cibrik D; Chan L; Kim YS; Carmellini M; Walker R; Zibari G; Pattison J; Cornu-Artis C; Wang Z; Tedesco-Silva H
Clin Transplant; 2013; 27(2):217-26. PubMed ID: 23230975
[TBL] [Abstract][Full Text] [Related]
19. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment.
Hiramitsu T; Okada M; Futamura K; Yamamoto T; Tsujita M; Goto N; Narumi S; Watarai Y; Takeda A; Iwasaki K; Uchida K; Kobayashi T
Int Immunopharmacol; 2016 Oct; 39():192-198. PubMed ID: 27491025
[TBL] [Abstract][Full Text] [Related]
20. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
Lin M; Mittal S; Sahebjam F; Rana A; Sood GK
Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]